{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:58:31Z","timestamp":1790427511685,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.amjcard.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:18:29Z","timestamp":1784071109000},"page":"73-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Anticoagulant Regimen for Nonvalvular Atrial Fibrillation in the Elderly and Frail Population"],"prefix":"10.1016","volume":"277","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8429-1619","authenticated-orcid":false,"given":"Lorenzo","family":"Scalia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Agnello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9445-4294","authenticated-orcid":false,"given":"Dario","family":"Calderone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihail","family":"Celeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Popolo Rubbio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Barbanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.amjcard.2026.07.006_bib0001","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J."},{"issue":"24","key":"10.1016\/j.amjcard.2026.07.006_bib0002","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.3390\/jcm11247423","article-title":"Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study","volume":"11","author":"Bonanad","year":"2022","journal-title":"J Clin Med."},{"issue":"5","key":"10.1016\/j.amjcard.2026.07.006_bib0003","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacasi.2024.02.002","article-title":"Impact of Aging on Cardiovascular Diseases: From Chronological Observation to Biological Insights: JACC Family Series","volume":"4","author":"Zhao","year":"2024","journal-title":"JACC Asia."},{"issue":"1","key":"10.1016\/j.amjcard.2026.07.006_bib0004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol."},{"issue":"2","key":"10.1016\/j.amjcard.2026.07.006_bib0005","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1152\/physrev.00037.2021","article-title":"Multisystem physiological perspective of human frailty and its modulation by physical activity","volume":"103","author":"Taylor","year":"2023","journal-title":"Physiol Rev."},{"issue":"3","key":"10.1016\/j.amjcard.2026.07.006_bib0006","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"3","key":"10.1016\/j.amjcard.2026.07.006_bib0007","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1532-5415.2009.02137.x","article-title":"A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men","volume":"57","author":"Ensrud","year":"2009","journal-title":"J Am Geriatr Soc."},{"issue":"12","key":"10.1016\/j.amjcard.2026.07.006_bib0008","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/jgs.18001","article-title":"Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants","volume":"70","author":"Candeloro","year":"2022","journal-title":"J Am Geriatr Soc."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101652","article-title":"Frailty prevalence and impact on outcomes in patients with atrial fibrillation: A systematic review and meta-analysis of 1,187,000 patients","volume":"79","author":"Proietti","year":"2022","journal-title":"Ageing Research Reviews"},{"issue":"1","key":"10.1016\/j.amjcard.2026.07.006_bib0010","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med."},{"issue":"5","key":"10.1016\/j.amjcard.2026.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/jcm11051370","article-title":"Impact of multimorbidity and polypharmacy on clinical outcomes of elderly chinese patients with atrial fibrillation","volume":"11","author":"Kotalczyk","year":"2022","journal-title":"Journal of, Clin. Med."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0012","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2018.09.017","article-title":"Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial","volume":"208","author":"Alexander","year":"2019","journal-title":"Am Heart J."},{"issue":"6","key":"10.1016\/j.amjcard.2026.07.006_bib0013","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1007\/s12325-021-01724-8","article-title":"Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity","volume":"38","author":"Deitelzweig","year":"2021","journal-title":"Adv Ther."},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0014","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/joim.12236","article-title":"Risk of falls and bleeding in elderly patients with acute venous thromboembolism","volume":"276","author":"K\u00e4mpfen","year":"2014","journal-title":"J Intern Med."},{"issue":"2","key":"10.1016\/j.amjcard.2026.07.006_bib0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jgs.16822","article-title":"Geriatric syndromes and atrial fibrillation: prevalence and association with anticoagulant use in a national cohort of older americans","volume":"69","author":"Shah","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"issue":"16","key":"10.1016\/j.amjcard.2026.07.006_bib0016","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1001\/jama.2024.1416","article-title":"Risk Assessment and Prevention of Falls in Older Community-Dwelling Adults: A Review","volume":"331","author":"Col\u00f3n-Emeric","year":"2024","journal-title":"JAMA."},{"issue":"7","key":"10.1016\/j.amjcard.2026.07.006_bib0017","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/CIRCULATIONAHA.110.007864","article-title":"Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation","volume":"124","author":"Poli","year":"2011","journal-title":"Circulation."},{"issue":"11","key":"10.1016\/j.amjcard.2026.07.006_bib0018","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1055\/s-0041-1726345","article-title":"Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism","volume":"121","author":"Frei","year":"2021","journal-title":"Thromb Haemost."},{"issue":"11","key":"10.1016\/j.amjcard.2026.07.006_bib0019","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40264-022-01231-x","article-title":"Efficacy and safety of anticoagulants in patients with atrial fibrillation and history of falls or risk of falls: a systematic review and multilevel meta-analysis","volume":"45","author":"Galvain","year":"2022","journal-title":"Drug Saf."},{"issue":"16","key":"10.1016\/j.amjcard.2026.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J."},{"issue":"1","key":"10.1016\/j.amjcard.2026.07.006_bib0021","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11606-014-2993-8","article-title":"Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism","volume":"30","author":"Leiss","year":"2015","journal-title":"J Gen Intern Med."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114064","article-title":"Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?","volume":"158","author":"Mart\u00ednez-Montesinos","year":"2023","journal-title":"Biomed Pharmacother."},{"issue":"3","key":"10.1016\/j.amjcard.2026.07.006_bib0023","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/jgs.15712","article-title":"Relevance of Polypharmacy for Clinical Outcome in Patients Receiving Vitamin K Antagonists","volume":"67","author":"Eggebrecht","year":"2019","journal-title":"J Am Geriatr Soc."},{"issue":"02","key":"10.1016\/j.amjcard.2026.07.006_bib0024","first-page":"135","article-title":"The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"124","author":"Grymonprez","year":"2023","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.thromres.2020.07.054","article-title":"The increased risk of bleeding due to drug-drug interactions in patients administered direct oral anticoagulants","volume":"195","author":"Lee","year":"2020","journal-title":"Thromb Res."},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0026","first-page":"279","article-title":"Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0027","first-page":"236","article-title":"Measuring frailty: Developing and testing the GFI (Groningen Frailty Indicator)","volume":"41","author":"Steverink","year":"2001","journal-title":"Gerontologist"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0028","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"Journal of Thrombosis and Haemostasis."},{"issue":"18","key":"10.1016\/j.amjcard.2026.07.006_bib0029","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.amjcard.2026.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.amjcard.2026.07.006_bib0031","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.amjcard.2026.07.006_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.amjcard.2026.07.006_bib0033","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0034","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0035","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.amjcard.2026.07.006_bib0036","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J."},{"issue":"22","key":"10.1016\/j.amjcard.2026.07.006_bib0037","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0038","first-page":"686","article-title":"Edoxaban: an investigational factor xa inhibitor","volume":"39","author":"Hughes","year":"2014","journal-title":"P T"},{"issue":"12","key":"10.1016\/j.amjcard.2026.07.006_bib0039","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab Dispos."},{"issue":"7","key":"10.1016\/j.amjcard.2026.07.006_bib0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"10.1016\/j.amjcard.2026.07.006_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","article-title":"Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor","volume":"13","author":"Mendell","year":"2013","journal-title":"Am J Cardiovasc Drugs."},{"issue":"5","key":"10.1016\/j.amjcard.2026.07.006_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc."},{"issue":"6","key":"10.1016\/j.amjcard.2026.07.006_bib0043","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jacasi.2022.07.008","article-title":"Oral Anticoagulants in Very Elderly Nonvalvular Atrial Fibrillation Patients With High Bleeding Risks: ANAFIE Registry","volume":"2","author":"Okumura","year":"2022","journal-title":"JACC Asia"},{"issue":"1","key":"10.1016\/j.amjcard.2026.07.006_bib0044","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation."},{"issue":"6","key":"10.1016\/j.amjcard.2026.07.006_bib0045","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/STROKEAHA.121.036757","article-title":"Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation","volume":"53","author":"Kim","year":"2022","journal-title":"Stroke"},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0046","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/CIRCULATIONAHA.123.067555","article-title":"Switching to Direct Anticoagulation or Continued Vitamin-K Antagonists in Frail Patients With Atrial Fibrillation in Whom Vitamin-K Antagonists Are Tolerated?","volume":"149","author":"Wallentin","year":"2024","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0047","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s41999-023-00811-z","article-title":"Anticoagulant use in older persons at risk for falls: therapeutic dilemmas-a clinical review","volume":"14","author":"Mitchell","year":"2023","journal-title":"Eur Geriatr Med."},{"issue":"8","key":"10.1016\/j.amjcard.2026.07.006_bib0048","doi-asserted-by":"crossref","first-page":"afac192","DOI":"10.1093\/ageing\/afac192","article-title":"Epidemiology and impact of frailty in patients with atrial fibrillation in Europe","volume":"51","author":"Proietti","year":"2022","journal-title":"Age Ageing."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.archger.2024.105602","article-title":"Atrial fibrillation management in older hospitalized patients: Evidence of a poor oral anticoagulants prescriptive attitude from the Italian REPOSI registry","volume":"128","author":"Arcoraci","year":"2025","journal-title":"Archives of Gerontology and Geriatrics"},{"issue":"3_Part_2","key":"10.1016\/j.amjcard.2026.07.006_bib0050","first-page":"488","article-title":"Anticoagulation in Elderly Patients With Atrial Fibrillation and Renal Dysfunction","volume":"3","author":"Cheung","year":"2023","journal-title":"JACC: Asia."},{"issue":"2","key":"10.1016\/j.amjcard.2026.07.006_bib0051","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in Patients with Chronic Kidney Disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.amjcard.2026.07.006_bib0052","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5770\/cgj.24.475","article-title":"Factors Associated With Patient Engagement in Shared Decision-Making for Stroke Prevention Among Older Adults with Atrial Fibrillation","volume":"24","author":"Mehawej","year":"2021","journal-title":"Can Geriatr J."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0053","first-page":"1","article-title":"Diagnostic Accuracy of the HAS-BLED Bleeding Score in VKA- or DOAC-Treated Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis","volume":"8","author":"Xinxing","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0054","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/ijerph22020179","article-title":"Atrial Fibrillation as a Geriatric Syndrome: Why Are Frailty and Disability Often Confused? A Geriatric Perspective from the New Guidelines","volume":"22","author":"Testa","year":"2025","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.amjcard.2026.07.006_bib0056","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and Validation of the PRECISE-HBR Score to Predict Bleeding After Percutaneous Coronary Intervention","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0057","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.carrev.2024.04.022","article-title":"Application of the Academic Research Consortium High Bleeding Risk criteria in patients treated with coronary bioresorbable polymer everolimus-eluting stents: Insights from the POEM trial","volume":"67","author":"Popolo Rubbio","year":"2024","journal-title":"Cardiovasc Revasc Med."},{"issue":"10206","key":"10.1016\/j.amjcard.2026.07.006_bib0058","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.amjcard.2026.07.006_bib0059","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.07.006_bib0060","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s10557-018-6795-9","article-title":"Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: A Systematic Review and Meta-Analysis","volume":"32","author":"Andreou","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0061","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"Gargiulo","year":"2019","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.amjcard.2026.07.006_bib0062","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.4244\/EIJ-D-21-01044","article-title":"Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry","volume":"18","author":"Chandrasekhar","year":"2022","journal-title":"EuroIntervention"},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0063","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/FJC.0000000000001607","article-title":"Management of Patients Treated With Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention With Stent Implantation: The PERSEO Registry","volume":"84","author":"Sciahbasi","year":"2024","journal-title":"J Cardiovasc Pharmacol."},{"issue":"16","key":"10.1016\/j.amjcard.2026.07.006_bib0064","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","article-title":"Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation","volume":"393","author":"Lemesle","year":"2025","journal-title":"N Engl J Med."},{"issue":"22","key":"10.1016\/j.amjcard.2026.07.006_bib0065","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","article-title":"Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med."},{"issue":"14","key":"10.1016\/j.amjcard.2026.07.006_bib0066","doi-asserted-by":"crossref","first-page":"e898","DOI":"10.4244\/EIJ-D-24-00100","article-title":"Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial","volume":"20","author":"Verburg","year":"2024","journal-title":"EuroIntervention"},{"issue":"11","key":"10.1016\/j.amjcard.2026.07.006_bib0067","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and Clinical Development of Factor XI Inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0068","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1056\/NEJMoa2406674","article-title":"Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation","volume":"392","author":"Ruff","year":"2025","journal-title":"N Engl J Med."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101761","article-title":"Impact of frailty models on the prescription of oral anticoagulants and on the incidence of stroke, bleeding, and mortality in older patients with atrial fibrillation: a systematic review","volume":"82","author":"Presta","year":"2022","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0070","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijcard.2016.08.001","article-title":"NT-proBNP is a powerful predictor for incident atrial fibrillation - Validation of a multimarker approach","volume":"223","author":"Svennberg","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.amjcard.2026.07.006_bib0071","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s41999-021-00537-w","article-title":"Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines","volume":"13","author":"Polidori","year":"2022","journal-title":"Eur Geriatr Med."},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0072","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/17434440.2022.2070005","article-title":"Mobile health technology in atrial fibrillation","volume":"19","author":"Bonini","year":"2022","journal-title":"Expert Review of Medical Devices"},{"issue":"4","key":"10.1016\/j.amjcard.2026.07.006_bib0073","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/ehjdh\/ztaf056","article-title":"Clinical feasibility of a quick response code-based digital self-reporting of medication adherence: results in patients on ticagrelor therapy from the APOLLO-QR observational study","volume":"6","author":"Francaviglia","year":"2025","journal-title":"Eur Heart J Digit Health."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0074","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ijcard.2020.12.008","article-title":"Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems","volume":"327","author":"Capranzano","year":"2021","journal-title":"Int J Cardiol."},{"issue":"3","key":"10.1016\/j.amjcard.2026.07.006_bib0075","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.hrthm.2017.11.007","article-title":"Detection of new atrial fibrillation in patients with cardiac implanted electronic devices and factors associated with transition to higher device-detected atrial fibrillation burden","volume":"15","author":"Boriani","year":"2018","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.amjcard.2026.07.006_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.132921","article-title":"Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions","volume":"422","author":"De Sio","year":"2025","journal-title":"Int J Cardiol."},{"issue":"14","key":"10.1016\/j.amjcard.2026.07.006_bib0077","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1161\/CIRCULATIONAHA.117.028845","article-title":"Subclinical Atrial Fibrillation in Older Patients","volume":"136","author":"Healey","year":"2017","journal-title":"Circulation"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926004455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926004455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:15:18Z","timestamp":1790424918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926004455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":77,"alternative-id":["S0002914926004455"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.07.006","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant Regimen for Nonvalvular Atrial Fibrillation in the Elderly and Frail Population","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}